stockportfolio.pro
Stocks / BIIB vs DXCM
BIIB vs DXCM
Biogen Inc. and DexCom, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Biogen Inc. (BIIB) | DexCom, Inc. (DXCM) | |
|---|---|---|
| Market cap | $29.4B | $30.2B |
| Revenue (latest FY) | $9.89B | $4.66B |
| Net income (latest FY) | $1.29B | $836.30M |
| Revenue growth (5y CAGR) | -6.0% | 19.3% |
| Net margin | 13.1% | 17.9% |
| Return on equity | 7.1% | 30.5% |
| P/E ratio | 21.4 | 32.9 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIIB — free Open DXCM — freeFrequently asked questions
Which is bigger, BIIB or DXCM?
DexCom, Inc. is larger by market capitalization — $30.2B versus $29.4B.
Which grows faster, BIIB or DXCM?
Over the last five fiscal years, DexCom, Inc. grew revenue faster — 19.3%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.